DRTS
Alpha Tau Medical Ltd.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 3 ▼ 1 insider sell $352.1K at $10.83
- Jun 23 to Jul 6 ▼ 6 days of insider sells: $919.0K by 1 insider, avg $11.52
- Jul 21 ▲ Alpha Tau reported positive clinical data from a study of Alpha DaRT…
- Aug 11 ▼ 1 insider sell $248.3K at $14.00
- Aug 21 ▼ 1 insider sell $43.1K at $15.00
- Oct 19 ▲ Alpha Tau announced FDA approval to expand its U.S. REGAIN trial for…
- Oct 19 ▲ Alpha Tau Medical announced FDA approval of an IDE supplement expand…
- Oct 22 Contract: Alpha Tau and Samsung Medical Center Sign MOU to Explore C…
- Oct 29 Activist stake: Alpha Tau Announces Inclusion in the Flagship TA-90 and TA…
- Nov 11 ▲ Piper Sandler upgrades
- Nov 15 FDA: Alpha Tau Announces New Positive Interim Results from its…
- Nov 15 ▲ Alpha Tau Medical announced updated interim results from its REGAIN…
- Nov 16 New report: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $1.6M.
- InstitutionsBULLISH
Q3 2026: 15 added (0 new), 6 trimmed or exited.
- AnalystsBULLISH
9 of 11 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.142 → −$0.152 over 90 days. 1 up, 3 down in 30 days.
- Short sellersSTEADY
Short interest +14.1% to 3.92M shares. 8.1 days to cover, ≈4.2% of shares.
- TrendDOWNTREND
15% below its 50-day average.
- SocialQUIET
Crowd 50° (neutral) this week from 3 mentions: 0 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | DOUBLED | $20.8M |
| UBS Group AG | ADD | $18.7M |
| ARK Investment Management LLC | TRIM | $2.7M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | $2.3M |
| MORGAN STANLEY | DOUBLED | $1.9M |
| Focus Partners Wealth | NEAR_EXIT | $481.1K |
| Squarepoint Ops LLC | ADD | $417.7K |
| JANE STREET GROUP, LLC | TRIM | $402.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
11 analystsPrice is below the lowest target. Median implies +50%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 11, 2026 | Piper Sandler UPGRADE | Overweight |
| Oct 20, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 3, 2026 | Barclays MAINTAIN | Overweight |
| Aug 11, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Jul 22, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Jul 16, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Levy Raphi Chief Financial Officer Aug 21, 2026 | EXERCISE | $8.6K |
Levy Raphi Chief Financial Officer Aug 21, 2026 | SELL | $43.1K |
Levy Raphi Chief Financial Officer Aug 11, 2026 | SELL | $248.3K |
Levy Raphi Chief Financial Officer Aug 11, 2026 | EXERCISE | $52.8K |
Levy Raphi Chief Financial Officer Jul 6, 2026 | EXERCISE | $6.8K |
Levy Raphi Chief Financial Officer Jul 6, 2026 | SELL | $31.8K |
Levy Raphi Chief Financial Officer Jul 2, 2026 | EXERCISE | $53.3K |
Levy Raphi Chief Financial Officer Jul 2, 2026 | SELL | $232.4K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.15 | -$0.16–-$0.15 | -3.4% | $166.7K |
| Next Q | -$0.16 | -$0.17–-$0.15 | -3.3% | $333.3K |
| Current FY | -$0.96 | -$1.08–-$0.55 | -0.8% | $503.3K |
| Next FY | -$0.54 | -$0.60–-$0.50 | -0.7% | $10.7M |
Short side
FINRA· Oct 30, 2026SecBot reports
14 filings · 11 press releases · 8 bullish · 0 bearish · 1 mixed · 5 neutral- BULLISH 6-KNov 16, 2026
Alpha Tau Medical reported interim results from its REGAIN trial of Alpha DaRT in recurrent glioblastoma, showing 100% feasibility, no unanticipated serious adverse events, all 8 patients alive, and a 6/6 objective response rate (5 complete, 1 partial) in assessed patients. The data were presented…
🔒 Fresh report (last 24h), subscribers only
- BULLISH 6-KNov 16, 2026
Alpha Tau reported updated interim results from its REGAIN trial of Alpha DaRT for recurrent glioblastoma. All eight treated patients were alive as of the November 11, 2026 cutoff, with median overall survival not reached at a median follow-up of 6.9 months.
🔒 Fresh report (last 24h), subscribers only
- BULLISH PRESS RELEASENov 15, 2026
Alpha Tau Medical announced updated interim results from its REGAIN trial of Alpha DaRT for…
Monitor upcoming scans for confirmation of responses and differentiation between necrosis and tumor progression; watch for enrollment completion and any regulatory submission discussions. The…
- NEUTRAL 6-KNov 12, 2026
Alpha Tau Medical Ltd. filed a Form 6-K announcing a conference call and webcast on Nov. 16, 2026…
The interim data from the REGAIN trial, when presented on Nov. 16, could provide the first clinical evidence of Alpha DaRT's safety and feasibility in glioblastoma. Positive results may support…
All DRTS filing & press-release reports (25)
- 6-K reportNov 16, 2026
- 6-K reportNov 16, 2026
- PRESS-RELEASE reportNov 15, 2026
- 6-K reportNov 12, 2026
- 6-K reportOct 29, 2026
- PRESS-RELEASE reportOct 29, 2026
- 6-K reportOct 22, 2026
- PRESS-RELEASE reportOct 22, 2026
- 6-K reportOct 19, 2026
- PRESS-RELEASE reportOct 19, 2026
- 6-K reportAug 31, 2026
- 6-K reportAug 10, 2026
- PRESS-RELEASE reportAug 10, 2026
- 6-K reportAug 10, 2026
- 6-K reportJul 21, 2026
- 6-K reportJul 15, 2026
- 6-K reportJun 23, 2026
- PRESS-RELEASE reportJun 3, 2026
- PRESS-RELEASE reportMay 11, 2026
- PRESS-RELEASE reportMay 8, 2026
- PRESS-RELEASE reportMay 5, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportApr 27, 2026
- PRESS-RELEASE reportApr 23, 2026
- PRESS-RELEASE reportMar 9, 2026